Concepedia

Thomas Segiet

TS

Statistics

Publications

8

Citations

4.7K

H-Index

8

Active since

2011

Affiliations

University of Toronto(Current)

Semmelweis University

Heidelberg University

Eli Lilly (United States)

Université Laval

Thomas Segiet is an author at University of Toronto specializing in diabetes mellitus, diabetology, and medicine.

Publications per year

2011–2021

8

Publications

8

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 305 citations · Full text

Public Health, Endocrinology, Genetics +13

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes

Baptist Gallwitz, Michael Böhmer, Thomas Segiet et al. · Diabetes Care · 2011 · 89 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

1–5 of 8